Skip to main content
CYCLOPHARM LIMITED logo

CYCLOPHARM LIMITED — Investor Relations & Filings

Ticker · CYC ISIN · AU000000CYC5 LEI · 9845008C9R4608FB7007 ASX Manufacturing
Open in API
Filings indexed 777 across all filing types
Latest filing 2018-03-25 Governance Information
Country AU Australia
Listing ASX CYC

About CYCLOPHARM LIMITED

https://www.cyclopharm.com.au

Cyclopharm Limited focuses on the development and commercialization of specialized medical imaging technologies. Its primary product, Technegas, is an ultra-fine dispersion of carbon nano-particles labeled with Technetium-99m, utilized for functional lung ventilation imaging. This technology is used to diagnose Pulmonary Embolism by providing high-resolution images via the inhalation of a radioactive aerosol. Technegas is generated on-site using proprietary equipment and is compatible with SPECT and SPECT/CT imaging. The system is engineered to provide diagnostic clarity even in patients with underlying airway diseases. Beyond its primary diagnostic use, the company investigates applications for its technology in managing chronic obstructive pulmonary disease (COPD), asthma, and lung cancer.

Recent filings

Filing Released Lang Actions
CYC Appendix 4G 10 pages 226.6KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G' and references ASX Listing Rules 4.7.3 and 4.10.3, which pertain to corporate governance disclosures required to be lodged with the ASX alongside the annual report. The content is a detailed key to disclosures against the Corporate Governance Council Principles and Recommendations for the financial year ended 31 December 2017. It includes a corporate governance statement approved by the board and references to where the full statement can be found (either in the annual report or on the website). The document is focused on governance practices, board structure, and compliance with governance recommendations rather than financial results or operational data. It is not an annual report itself but a governance disclosure document required by regulatory rules. This fits the definition of a Governance Information (CGR) filing, which details the company's internal rules, board structure, and governance practices. The document length (15,000 characters) and detailed content confirm it is a substantive governance report rather than a brief announcement or certification. Therefore, the appropriate classification is CGR with high confidence.
2018-03-25 English
2017 Results Presentation 31 pages 1.7MB
Investor Presentation Classification · 95% confidence The document is titled '2017 Results Presentation March 2018' and contains detailed information about Cyclopharm Limited's financial results for the fiscal year 2017, including sales revenue, net loss, dividends, and EBITDA. It also includes strategic information, product overviews, market opportunities, clinical trial updates, and future guidance. The content is structured as a presentation with slides covering company overview, strategy, product details, market data, and clinical trial progress. The document length is 15,000 characters, indicating a comprehensive presentation rather than a brief announcement. The presence of detailed financial results and strategic outlook aligns with the characteristics of an Investor Presentation (IP) rather than an Annual Report (10-K) or Earnings Release (ER), which are typically more formal and regulatory in nature. There is no indication that this is a regulatory filing, certification, or a report publication announcement. Therefore, the document is best classified as an Investor Presentation (IP).
2018-03-14 English
Change of Director's Interest Notice - David Heaney 2 pages 588.9KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details a director's change in relevant interests in securities, including the number of shares held before and after the change, the nature of the change (on-market trade), and other related information. The document is a formal notification of a director's personal share transactions. It does not contain financial statements, earnings data, or management discussion. It is not an annual report, earnings release, or any other financial report type. This matches the definition of 'Director's Dealing' filings, which report personal share transactions by company directors and executives (insider trades). The document length is 3281 characters, consistent with a short notice rather than a full report. Therefore, the correct classification is DIRS (Director's Dealing).
2018-02-28 English
Dividend/Distribution - CYC 3 pages 26.6KB
Notice of Dividend Amount Classification · 100% confidence The document is a notification of dividend/distribution for Cyclopharm Limited, detailing the dividend amount, ex-date, record date, and payment date. It does not contain financial statements or detailed financial analysis but is an announcement of dividend payment details. The document length is under 5,000 characters and is clearly an announcement rather than a full report. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2018-02-25 English
Preliminary Final Report 71 pages 599.4KB
Annual Report Classification · 95% confidence The document is titled 'Cyclopharm Limited Appendix 4E' and includes detailed financial results for the year ended 31 December 2017. It contains comprehensive financial data such as revenues, net loss, EBITDA, cash flows, dividends, and commentary on results. The document also includes a Managing Director's Report with detailed explanations of financial performance, strategic initiatives, and operational highlights. The presence of full financial statements and detailed management discussion indicates this is a comprehensive annual financial report. Appendix 4E is a regulatory form used in Australia for preliminary final reports, which are annual reports summarizing the full year financial results. The document is not merely an announcement or a brief summary but contains substantive financial data and analysis. Therefore, the appropriate classification is Annual Report (10-K equivalent). FY 2017
2018-02-25 English
CYC Reports Solid FY2017 Results - Maintains Dividend 4 pages 160.6KB
Earnings Release Classification · 95% confidence The document is a detailed financial and operational results announcement for the fiscal year ended December 31, 2017. It includes comprehensive financial data such as sales revenue, EBITDA, net loss, cash position, and dividend declaration. It also discusses operational highlights, strategic progress, clinical trials, acquisitions, and outlook for the next year. The document is about the full year financial performance and business activities, which aligns with the characteristics of an Annual Report (10-K equivalent) or an Earnings Release. However, the length (over 10,000 characters) and the depth of financial and operational detail, including full year results and dividend declaration, indicate it is more than a brief earnings release. It is a full fiscal year results report with detailed financials and management commentary, typical of an Annual Report or a comprehensive Earnings Release. Given the document is titled "CYC REPORTS SOLID FY2017 RESULTS – MAINTAINS DIVIDEND" and contains detailed financial tables and operational summaries, it fits best as an Earnings Release (ER) rather than a full Annual Report (10-K), which would be more extensive and include audited financial statements and notes. Therefore, the classification is Earnings Release (ER). FY 2017
2018-02-25 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.